BioSpace News Archive

Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab)

A powerful, real-world evidence study designed by McKesson Specialty Health for its biopharma partner played a key role in the Food and Drug Administration’s (FDA) approval for first-line indication for a rare disease.

System is designed for use in clinical trials and research studies where collection of relevant data is needed.

Company Also Announces Five Active Global Trials and Plans to License Patent-Pending Software

Lower generic cost share, missed refill interventions may yield better health, higher Star Ratings

Verastem, Inc., (Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients, today announced the pricing of its registered underwritten public offering of 7,777,778 shares of its common stock at a price to the public of $4.50 per share

—Investigational vaccine designed to generate broad and durable immune protection over multiple influenza seasons —Subjects challenged with influenza virus genetically drifted by six years from vaccine strain —Study supported by U.S. Department of Defense

PharmaCyte Biotech, Inc. (OTCQB: PMCB), today announced that the cells it will encapsulate and then use in its planned clinical trial have successfully passed all 29 tests required by the U.S. Food and Drug Administration (FDA)

Jay Leno and Chris Isaak, as well as patients, philanthropists, leading national Lyme disease researchers and clinicians, observe a moment of silence for those who have died from the disease, including four women from the San Francisco Bay Area

In just one year, customers of the Inside Rx® prescription savings program collectively have saved $100 million on their medications.